Lamisil 1% cream 15g in tube
- $29.50
The instruction for use of medicine for experts
of LAMIZILT (LAMISIL®)
the Trade name
of LAMIZILT
the International unlicensed
name Terbinafin Lekarstvennaya a form
Cream for external use of 1%
Structure
of 1 g of cream contains
active agent - a terbinafin hydrokhlorida10 mg,
excipients: benzyl alcohol, sodium hydroxide, sorbitan stearate, tsetit palmitate, stearyl alcohol, cetyl alcohol, polysorbate 60, an isopropyl myristate, water purified.
The description
White uniform cream with a slight characteristic smell
Pharmacotherapeutic group
Antifungal means
the Code of automatic telephone exchange D01AE15
the Pharmacological
Pharmacokinetics At properties topical administration absorption – less than 5%,
the Pharmacodynamics
the Antifungal drug for topical administration possessing a wide range of antifungal activity has insignificant systemic action.
In small concentration Lamizil has fungicide effect concerning dermatophytes (Trychophyton rubrum, T.mentagrophytes, T.verrucosum, T.violaceum, T.tonsurans, Microsporum canis, Epidermophyton floccosum), mold (in the main C.albicans) and certain dimorphous mushrooms (Pityrosporum orbiculare).
The activity concerning barmy mushrooms, depending on their look, can be fungicidal or fungistatic.
Lamizil in unusual way changes an early stage of the biosynthesis of sterols happening in mushrooms. It leads to deficiency of ergosterol and to intracellular accumulation of squalene that causes death of a cell of a mushroom.
Lamizil's action is carried out by inhibition of the enzyme of a skvalenepoksidaza located on a cellular membrane of a mushroom.
Lamizil does not influence the system of P450 cytochrome at the person and, respectively, metabolism of hormones or other medicines.
Indications
- prevention and treatment of fungal infections of skin
- the mycoses of feet, orogovelost, cracks, an itching and peeling of skin
caused by a fungus
- an inguinal epidermophitia
- the fungal infections of smooth skin of a body (tinea corporis) caused
by Trichophyton dermatophytes (including, T. rubrum, T. mentagrophytes,
T. verrucosum, T. violaceum), Microsporum canis and Epidermophyton floccosum
- the skin candidiasis caused by the sort Candida (Candida albicans), an intertrigo
- multi-colored deprive (Pityriasis versicolor), the caused
Pityrosporum orbiculare (Malassezia furfur)
the Route of administration and doses
Outwardly
Adults and children from 12 years
Before putting cream it is necessary to clean and dry affected areas. Cream is applied by one or two times a day with a thin layer on the affected skin and adjacent sites and slightly rub.
In the infections which are followed by an intertrigo (under mammary glands, in interdigital intervals, between buttocks, in inguinal area), sites of application of cream can be covered with a gauze, especially for the night.
Average duration of treatment:
- dermatomycosis of a trunk, shins: 1 week once a day
- a dermatomycosis of feet: 1 week once a day
- orogovelost, cracks, an itching and the peeling of skin caused by a fungus -
feet – 2 weeks 1-2 times a day
- skin candidiasis: 1 or 2 times a day
- multi-colored deprive 1-2 weeks: 2 weeks 1 or 2 times a day
Reduction of expressiveness of clinical manifestations are usually celebrated in the first days of treatment.
In case of irregular treatment or its premature termination there is a risk of resuming of an infection.
If in two weeks of treatment signs of improvement are not noted, it is necessary to carry out verification of the diagnosis.
The mode of dosing Lamizila of cream at elderly people does not differ from the aforesaid.
Use of drug for children
is not recommended use of this drug for children up to 12 years.
Side effects
- reddening, feeling of an itching or burning in sites of application of drug
- allergic reactions
of the Contraindication to use
- hypersensitivity to a terbinafin or to any of
the inactive ingredients which are a part of drug
- children's age up to 12 years
Medicinal interactions
Any medicinal interactions for Lamizil of cream are not known.
Special instructions
With care: the liver and/or renal failure, alcoholism, oppression of a marrowy hemopoiesis, a tumor, a metabolism disease, occlusal diseases of vessels of extremities,
Reduction of expressiveness of clinical manifestations is usually noted in the first days of treatment.
In case of irregular treatment or its premature termination there is a risk of a recurrence of an infection.
Lamizil cream is intended only for external use.
It is necessary to avoid hit it in eyes as it can cause irritation. At accidental hit of drug in eyes, they should be washed immediately with flowing water, and in case of development of the resistant phenomena of irritation it is necessary to consult with the doctor.
At development of allergic reactions it is necessary to cancel drug.
Pregnancy and a lactation
About cases of congenital anomalies at the person at use Lamizil it was not reported. However, as clinical experience of use of Lamizil for pregnant women is limited, use of external forms of drug during pregnancy is possible only according to strict indications.
Terbinofin is allocated with breast milk. However, in case of use by the nursing mother of Lamizil of cream through skin it is soaked up a small amount of active agent therefore an adverse effect on the baby is improbable
Overdose
About cases of overdose of the preaparat it was not reported. If accidentally Lamizil cream is accepted inside, it is possible to expect development of the same by-effects, as well as at overdose of the tablets Lamizila
(a headache, nausea, pains in epigastriums and dizziness).
Treatment: activated carbon, if necessary - symptomatic therapy.
A form of release and packing
On 15 g - a tuba aluminum with a protective membrane from aluminum, the cover from polypropylene supplied with a ledge for perforation of a membrane.
The tuba with the instruction for use is packed into a cardboard pack.
To Store storage conditions at a temperature not above 30 ºC
to Store out of children's reach!
Not to use an expiration date of 5 years after expiry date
Prescription status
Without prescription
the Name and the address
of Novartis Konsyyumer Hels SA manufacturing, Switzerland
Address: rue de Letraz, p.b. 269, 1260 Nion, Switzerland.
Novartis Consumer Health SA,
Switzerland Route de l'Etraz, Case postale 269, 1260 Nyon, Switzerland.
Representation in
Moscow 123104, Moscow, B. Palashevsky Lane, 15
Ph. (095) 969-21-65, fax 969-21-66 e-mail: consumerhealth@novartis.ru
of LAMIZILT (LAMISIL®)
the Trade name
of LAMIZILT
the International unlicensed
name Terbinafin Lekarstvennaya a form
Cream for external use of 1%
Structure
of 1 g of cream contains
active agent - a terbinafin hydrokhlorida10 mg,
excipients: benzyl alcohol, sodium hydroxide, sorbitan stearate, tsetit palmitate, stearyl alcohol, cetyl alcohol, polysorbate 60, an isopropyl myristate, water purified.
The description
White uniform cream with a slight characteristic smell
Pharmacotherapeutic group
Antifungal means
the Code of automatic telephone exchange D01AE15
the Pharmacological
Pharmacokinetics At properties topical administration absorption – less than 5%,
the Pharmacodynamics
the Antifungal drug for topical administration possessing a wide range of antifungal activity has insignificant systemic action.
In small concentration Lamizil has fungicide effect concerning dermatophytes (Trychophyton rubrum, T.mentagrophytes, T.verrucosum, T.violaceum, T.tonsurans, Microsporum canis, Epidermophyton floccosum), mold (in the main C.albicans) and certain dimorphous mushrooms (Pityrosporum orbiculare).
The activity concerning barmy mushrooms, depending on their look, can be fungicidal or fungistatic.
Lamizil in unusual way changes an early stage of the biosynthesis of sterols happening in mushrooms. It leads to deficiency of ergosterol and to intracellular accumulation of squalene that causes death of a cell of a mushroom.
Lamizil's action is carried out by inhibition of the enzyme of a skvalenepoksidaza located on a cellular membrane of a mushroom.
Lamizil does not influence the system of P450 cytochrome at the person and, respectively, metabolism of hormones or other medicines.
Indications
- prevention and treatment of fungal infections of skin
- the mycoses of feet, orogovelost, cracks, an itching and peeling of skin
caused by a fungus
- an inguinal epidermophitia
- the fungal infections of smooth skin of a body (tinea corporis) caused
by Trichophyton dermatophytes (including, T. rubrum, T. mentagrophytes,
T. verrucosum, T. violaceum), Microsporum canis and Epidermophyton floccosum
- the skin candidiasis caused by the sort Candida (Candida albicans), an intertrigo
- multi-colored deprive (Pityriasis versicolor), the caused
Pityrosporum orbiculare (Malassezia furfur)
the Route of administration and doses
Outwardly
Adults and children from 12 years
Before putting cream it is necessary to clean and dry affected areas. Cream is applied by one or two times a day with a thin layer on the affected skin and adjacent sites and slightly rub.
In the infections which are followed by an intertrigo (under mammary glands, in interdigital intervals, between buttocks, in inguinal area), sites of application of cream can be covered with a gauze, especially for the night.
Average duration of treatment:
- dermatomycosis of a trunk, shins: 1 week once a day
- a dermatomycosis of feet: 1 week once a day
- orogovelost, cracks, an itching and the peeling of skin caused by a fungus -
feet – 2 weeks 1-2 times a day
- skin candidiasis: 1 or 2 times a day
- multi-colored deprive 1-2 weeks: 2 weeks 1 or 2 times a day
Reduction of expressiveness of clinical manifestations are usually celebrated in the first days of treatment.
In case of irregular treatment or its premature termination there is a risk of resuming of an infection.
If in two weeks of treatment signs of improvement are not noted, it is necessary to carry out verification of the diagnosis.
The mode of dosing Lamizila of cream at elderly people does not differ from the aforesaid.
Use of drug for children
is not recommended use of this drug for children up to 12 years.
Side effects
- reddening, feeling of an itching or burning in sites of application of drug
- allergic reactions
of the Contraindication to use
- hypersensitivity to a terbinafin or to any of
the inactive ingredients which are a part of drug
- children's age up to 12 years
Medicinal interactions
Any medicinal interactions for Lamizil of cream are not known.
Special instructions
With care: the liver and/or renal failure, alcoholism, oppression of a marrowy hemopoiesis, a tumor, a metabolism disease, occlusal diseases of vessels of extremities,
Reduction of expressiveness of clinical manifestations is usually noted in the first days of treatment.
In case of irregular treatment or its premature termination there is a risk of a recurrence of an infection.
Lamizil cream is intended only for external use.
It is necessary to avoid hit it in eyes as it can cause irritation. At accidental hit of drug in eyes, they should be washed immediately with flowing water, and in case of development of the resistant phenomena of irritation it is necessary to consult with the doctor.
At development of allergic reactions it is necessary to cancel drug.
Pregnancy and a lactation
About cases of congenital anomalies at the person at use Lamizil it was not reported. However, as clinical experience of use of Lamizil for pregnant women is limited, use of external forms of drug during pregnancy is possible only according to strict indications.
Terbinofin is allocated with breast milk. However, in case of use by the nursing mother of Lamizil of cream through skin it is soaked up a small amount of active agent therefore an adverse effect on the baby is improbable
Overdose
About cases of overdose of the preaparat it was not reported. If accidentally Lamizil cream is accepted inside, it is possible to expect development of the same by-effects, as well as at overdose of the tablets Lamizila
(a headache, nausea, pains in epigastriums and dizziness).
Treatment: activated carbon, if necessary - symptomatic therapy.
A form of release and packing
On 15 g - a tuba aluminum with a protective membrane from aluminum, the cover from polypropylene supplied with a ledge for perforation of a membrane.
The tuba with the instruction for use is packed into a cardboard pack.
To Store storage conditions at a temperature not above 30 ºC
to Store out of children's reach!
Not to use an expiration date of 5 years after expiry date
Prescription status
Without prescription
the Name and the address
of Novartis Konsyyumer Hels SA manufacturing, Switzerland
Address: rue de Letraz, p.b. 269, 1260 Nion, Switzerland.
Novartis Consumer Health SA,
Switzerland Route de l'Etraz, Case postale 269, 1260 Nyon, Switzerland.
Representation in
Moscow 123104, Moscow, B. Palashevsky Lane, 15
Ph. (095) 969-21-65, fax 969-21-66 e-mail: consumerhealth@novartis.ru
Related Products
Globopharm Pharmatsoytishe Produktons und Handels GmbH (Austria)
Exoderil® (Naftifine) 1%, 10 ml solution (external application)
$30.30
Merckle GmbH for ratiopharm GmbH (Germany)
Dolobene Gel (Heparin, Dimethyl Sulfoxide, Dexpanthenol)
$19.00
